About OmniAb, Inc.
https://www.omniab.comOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.
CEO
Matthew W. Foehr
Compensation Summary
(Year 2023)
Price Target
Institutional Ownership
AVISTA CAPITAL HOLDINGS, L.P.
Shares:11.35M
Value:$1.02M
LMR PARTNERS LLP
Shares:897.39K
Value:$80.32K
ARISTEIA CAPITAL LLC
Shares:679.92K
Value:$60.85K
Summary
Showing Top 3 of 15
About OmniAb, Inc.
https://www.omniab.comOmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.24M ▼ | $15.72M ▼ | $-16.52M ▼ | -738.05% ▼ | $-0.14 ▲ | $-10.71M ▲ |
| Q2-2025 | $3.9M ▼ | $19.85M ▼ | $-15.88M ▲ | -407.36% ▲ | $-0.15 ▲ | $-14.57M ▼ |
| Q1-2025 | $4.15M ▼ | $23M ▼ | $-18.2M ▼ | -438.13% ▼ | $-0.17 ▼ | $-14.1M ▼ |
| Q4-2024 | $10.8M ▲ | $26.68M ▲ | $-13.07M ▲ | -120.96% ▲ | $-0.12 ▲ | $-8.27M ▲ |
| Q3-2024 | $4.17M | $23.94M | $-16.37M | -392.45% | $-0.16 | $-14.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $59.5M ▲ | $309.69M ▲ | $32.25M ▼ | $277.44M ▲ |
| Q2-2025 | $41.62M ▼ | $295.67M ▼ | $33.61M ▲ | $262.06M ▼ |
| Q1-2025 | $43.59M ▼ | $306.18M ▼ | $32.67M ▼ | $273.52M ▼ |
| Q4-2024 | $59.43M ▲ | $325.56M ▼ | $37.94M ▼ | $287.62M ▼ |
| Q3-2024 | $59.38M | $331.55M | $39.83M | $291.73M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.52M ▼ | $-9.76M ▼ | $-7.67M ▼ | $27.68M ▲ | $10.26M ▲ | $-9.95M ▼ |
| Q2-2025 | $-15.88M ▲ | $-5.15M ▲ | $12.3M ▲ | $236K ▲ | $7.39M ▲ | $-5.31M ▲ |
| Q1-2025 | $-18.2M ▼ | $-15.87M ▼ | $-878K ▼ | $44K ▼ | $-16.71M ▼ | $-16.08M ▼ |
| Q4-2024 | $-13.07M ▲ | $-3.87M ▲ | $385K ▼ | $3.85M ▼ | $362K ▼ | $-3.92M ▲ |
| Q3-2024 | $-16.37M | $-6.58M | $4.45M | $8.57M | $6.44M | $-6.73M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Service | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
CEO
Matthew W. Foehr
Compensation Summary
(Year 2023)
Price Target
Institutional Ownership
AVISTA CAPITAL HOLDINGS, L.P.
Shares:11.35M
Value:$1.02M
LMR PARTNERS LLP
Shares:897.39K
Value:$80.32K
ARISTEIA CAPITAL LLC
Shares:679.92K
Value:$60.85K
Summary
Showing Top 3 of 15